EUCTR2011-003486-15-AT进行中（未招募）不适用
A multi-center, randomized, double-blind, placebo-controlled, parallel group, polysomnography study to investigate safety and efficacy of the rotigotine transdermal patch in subjects with Restless Legs Syndrome and End-Stage Renal Disease requiring hemodialysis
CB BIOSCIENCES GmbH0 个研究点目标入组 48 人开始时间: 2012年1月10日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 48
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Subject is informed and given ample time and opportunity to think about her/his participation and has given her/his written informed consent.
- •2. Subject understands the investigational nature of the trial and is willing and able to comply with the trial requirements. Subject is willing to accept that he/she might be treated with placebo during the treatment period.
- •3. Subject is able to apply/remove the trial patches correctly.
- •4. Subject is male or female, and is = 18 and = 85 years of age.
- •5. Subject has a body mass index (BMI) of = 18kg/m2 and 40kg/m2.
- •6. Subject has end-stage renal disease (ESRD) requiring hemodialysis and has been on a regular dialysis schedule for at least 3 months prior to Screening (Visit 1)
- •7. Subject has hemoglobin concentration of = 8g/dL(4.97mmol/L) at Screening (Visit 1)
- •8. Subject has ferritin concentration of = 100ng/mL at Screening (Visit 1)
- •9. Subject has a diagnosis of RLS based on the 4 cardinal diagnostic clinical features according to the International Restless Legs Syndrome Study Group (IRLSSG):
- •a. An urge to move legs, usually accompanied or caused by uncomfortable and unpleasant sensations in the legs (The urge to move can be present without uncomfortable sensations. Arms or other body parts can also be affected.).
- •b. The urge to move or unpleasant sensations begin or worsen during periods of rest or inactivity such as lying or sitting.
- •c. The urge to move or unpleasant sensations are partially or totally relieved by movement, such as walking or stretching, at least as long as the activity continues.
- •d. The urge to move or unpleasant sensations are worse in the evening or night than during the day or only occur in the evening or night (When symptoms are very severe, the worsening at night may not be noticeable but must have been previously present.).
- •10. Subject has had an initial response to previous dopaminergic treatment for RLS, or has had no previous dopaminergic treatment (ie, de novo).
- •11. At Baseline (Visit 2), subject has a score of =15 points on the IRLS (indicating moderate to severe RLS).
- •12. At Baseline (Visit 2), subject has a score of =11 points on the RLS-DI (Diagnostic Index).
- •13. At Baseline (Visit 2), subject has a score of =4 points on the CGI Item 1 assessment (indicating moderately ill).
- •14. At Baseline (Visit 2), subject scores =15 PLMs per hour on the PLMI based on PSG (recorded during the second night) as assessed by the investigator.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 24
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 24
排除标准
- •2. Subject has narcolepsy or other hypersomnia (including sleep attacks/sudden onset of
- •sleep), either observed during local PSG, Multiple Sleep Latency Test (MSLT), or
- •Maintenance of Wakefulness Test (MWT) or evidenced by subject history.
- •3. Subject has clinically relevant polyneuropathy or varicosis which cannot be clearly differentiated from RLS symptoms in the opinion of the Investigator.
- •4. Subject has additional clinically relevant concomitant diseases, such as attention deficit hyperactivity disorder, akathisia, painful legs and moving toes.
- •5. Subject has other central nervous system diseases such as Parkinson’s disease, dementia, progressive supranuclear paresis, multisystem atrophy, Huntington’s Chorea, amyotrophic lateral sclerosis, or Alzheimer’s disease.
- •6. Subject has evidence of an impulse control disorder according to the modified Minnessota Impulsive Disorders Interview (mMIDI) at Screening (Visit 1).
- •7. Subject has a lifetime history of suicide attempt (including an active attempt, interrupted attempt, or aborted attempt), or has suicidal ideation in the past 6 months as indicated by a positive response (‘Yes’) to either Question 4 or Question 5 of the C-SSRS at Screening. (Visit1) or Baseline (Visit 2).
- •8. Subject has a prior history of psychotic episodes.
- •9. Subject has a history of chronic alcohol or drug abuse within the last 12 months.
- •10. Subject has any medical or psychiatric condition, which in the opinion of the investigator, can jeopardize or would compromise the subject’s well-being or ability to participate in this trial.
- •11. Subject has a history of symptomatic (not asymptomatic) orthostatic hypotension in the 6 months prior to Baseline (Visit 2).
- •12. Subject has clinically relevant cardiovascular disease which in the opinion of the Investigator could compromise the subject’s well-being or ability to participate in this trial.
- •13. Subject has clinically relevant venous or arterial peripheral vascular disease.
- •14. Subject has a malignant neoplastic disease requiring therapy within 12 months prior to Screening (Visit 1).
- •15. Subject is currently receiving treatment with any of the following drug classes: neuroleptics, norepinephrine and dopamine reuptake inhibitors (bupropion), gabapentin, budipine, dopamine antagonist antiemetics (except domperidone), opioids, monoamine oxidase (MAO) inhibitors, catechol O methyltransferase (COMT) inhibitors, or psychostimulants (eg, amphetamines). If subject has received such therapy, a Washout Period of at least 7 days prior to Baseline (Visit 2) is required before starting treatment in this study.
- •16. Subject is pregnant, nursing, or is a woman of child-bearing potential who is not surgically sterile, 2 years postmenopausal, or does not consistently use 2 combined effective methods of contraception (including at least 1 barrier method), unless sexually abstinent.
- •17. Subject pursues shift work or performs other continuous non-disease-related life conditions which do not allow regular sleep at night.
- •18. Subject has had previous treatment with dopamine agonists within a period of 14days prior to Baseline (Visit 2), or L-dopa within 7 days prior to Baseline (Visit 2).
- •19. Subject has a medical history indicating intolerability to dopaminergic therapy (if pre-treated) or has experienced augmentation when previously treated with any dopaminergic agent.
- •20. Subject has received previous treatment with rotigotine.
- •21. Subject has participated in another t
研究者
相似试验
进行中（未招募）
不适用
A multi-center, randomized, double-blind, placebo-controlled, crossover study in women with irritable bowel syndrome to evaluate feasibility and reproducibility of barostat assessments of colorectal sensation during colorectal distention and its pharmacological modulation using octreotideIrritable Bowel SyndromMedDRA version: 9.1Level: PTClassification code 10023003Term: Irritable bowel syndromeEUCTR2007-004994-25-GBovartis Pharma Services AG46
进行中（未招募）
1 期
A multi-center, randomized, double-blind, placebo-controlled phase III trial omparing the efficacy of bevacizumab in combination with rituximab and CHOP (RA-CHOP) versus rituximab and CHOP (R-CHOP) in previously untreated patients with CD20-positive diffuse large B-cell lymphoma (DLBCL) - MAIPreviously untreated patients with CD20-positive diffuse large B-cell lymphoma (DLBCL) who have low-intermediate, high-intermediate, or high-risk disease according to the IPI score and patients with bulky tumor (largest diameter = 7.5 cm) regardless of disease risk according to the IPI.MedDRA version: 8.1Level: LLTClassification code 10012818Term: Diffuse large B-cell lymphomaEUCTR2006-005520-16-HUF. Hoffmann-La Roche Ltd1,060
进行中（未招募）
不适用
A multi-center, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of 24 weeks treatment with vildagliptin in type 2 diabetes mellitus patients = 70 years (drug-naive or inadequately controlled on oral agents).EUCTR2010-022658-18-DEovartis Pharma Services AG280
进行中（未招募）
不适用
A multi-center, randomized, double-blind, placebo-controlled clinical trial to evaluate the effect of 52 weeks treatment with vildagliptin on left ventricular function in patients with type 2 diabetes and congestive heart failure.Type 2 DiabetesEUCTR2008-005012-41-CZovartis Pharma Services AG246
进行中（未招募）
不适用
Efficacy and safety of iron chelation therapy with deferasirox compared toplacebo in patients with myelodysplastic syndromes and transfusional ironoverloadEUCTR2009-012418-38-DKovartis Pharma Services AG210